Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Abstract | AIMS: METHODS AND RESULTS: Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77-0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77-0.99; P = 0.032) and Type 2 (0.77, 0.61-0.97; P = 0.025), but not Type 4 MI. CONCLUSION:
|
Authors | Harvey D White, Ph Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Andrejs Erglis, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Renato D Lopes, Kenneth W Mahaffey, Angele Moryusef, Robert Pordy, Matthew T Roe, Piyamitr Sritara, Pierluigi Tricoci, Andreas M Zeiher, Gregory G Schwartz, ODYSSEY OUTCOMES Investigators |
Journal | European heart journal
(Eur Heart J)
Vol. 40
Issue 33
Pg. 2801-2809
(09 01 2019)
ISSN: 1522-9645 [Electronic] England |
PMID | 31121022
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Cholesterol, LDL
- alirocumab
|
Topics |
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Cholesterol, LDL
(blood)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(blood, classification, prevention & control)
- Prospective Studies
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|